資源描述：
《舒尼替尼對(duì)裸鼠腎癌個(gè)性化治療實(shí)驗(yàn)探究》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、舒尼替尼對(duì)裸鼠腎癌個(gè)性化治療實(shí)驗(yàn)探究［摘要］目的明確血管內(nèi)皮生長(zhǎng)因子受體(VEGFR)及血小板衍生因子受體(PDGFR)在腎癌組織中表達(dá)情況，了解舒尼替尼的適用個(gè)體。方法建立裸鼠背部皮下人腎癌移植瘤模型，根據(jù)VEGFR-3.PDGFRa是否表達(dá)，分為VEGFR陽(yáng)性組、PDGFR陽(yáng)性組、雙陽(yáng)組、雙陰組，各組內(nèi)設(shè)給藥組與對(duì)照組。分別于藥后第5、20天及自然死亡后穿刺取活檢測(cè)定瘤組織中VEGFR-3.PDGFRa表達(dá)強(qiáng)度的變化，記錄生存時(shí)間。結(jié)果各給藥組之間生存時(shí)間的差別有統(tǒng)計(jì)學(xué)意義(F二32.58,P<0.001),VEGFR-3、PDGFRa表達(dá)強(qiáng)度呈下降趨勢(shì)。結(jié)
2、論舒尼替尼可延長(zhǎng)VEGFR-3、PDGFRa陽(yáng)性表達(dá)荷瘤裸鼠的總生存期，對(duì)腎癌個(gè)性化治療有一定的指導(dǎo)意義。［關(guān)鍵詞］舒尼替尼；裸鼠；腎癌；個(gè)性化治療［中圖分類號(hào)］R737.11［文獻(xiàn)標(biāo)識(shí)碼］A［文章編號(hào)］1673-7210(2012)07(a)-0031-02TheexperimentsofSunitinibpersonalizedtreatmentfornudemousekidneycancerSUNFeidaWANGDongwenBAITaoRUFengZHANGXuefengDepartmentofUrology,theFirstHospitalofSha
3、nxiMedicalUniversity,ShanxiProvince,Taiyuan030001,China[Abstract]ObjectiveToexplicittheexpressionofvascularendothelialgrowthfactorreceptor(VEGFR)andplateletderivativefactorreceptor(PDGFR)inthekidneycancer,andtounderstandSunitinibforindividualandresistanceoftheproductionprocess?Method
4、sModelsofhumanrenalcellcarcinomatransplantedsubcutaneouslywereestablished,accordingtotheexpressedVEGFRandPDGFR,whichwasdividedintoVEGFRpositivegroup,PDGFRpositivegroup,VEGFRandPDGFRbothpositivegroup,thedoublenegativegroup,andthetearnwasfurtherdividedintotreatmentgroupandcontrolgroup.
5、TheexpressionandchangelevelofVEGFR-3andPDGFRawereobservedafterthetreatmentin5thdays,20thdaysandna/turaldeathpiercingtakingbiopsyindeterminationtumortissue,respectively,thesurvivaltimewasrecorded.ResuItsThedifferentsbetweenthesurvivaltimesofthefourpositivegrouphadstatisticmeanings(=32
6、?58,〈0.001)?ThetrendoftheexpressinglevelofVEGFR-3andPDGFRawasdrawing.ConclusionSunitinibcanprolongtheoerallsurialoftumor-burdenednudemousewhichexpresssesVEGFR-3andPDGFRa,andithascertaindirectivesignificanceinpersonalizedtreatmentforkidneycancer.[Keywords]Sunitinib；Nodemouse；Kidneycan
7、cer；Personalizedtreatment腎癌(renalcellcarcinoma,RCC)是泌尿系統(tǒng)常見腫瘤，近年來發(fā)病率逐步增加，且發(fā)病年齡有年輕化的趨勢(shì)。RCC是血管最豐富的實(shí)體瘤之一[1],腫瘤的生長(zhǎng)和轉(zhuǎn)移離不開新生血管提供充的營(yíng)養(yǎng)及氧供，所以腫瘤血管靶向治療已逐步發(fā)展成為當(dāng)今腫瘤研究領(lǐng)域的主攻方向之一。舒尼替尼作為唯一突破晚期腎癌2年生存率的藥物，通過抑制VEGFR1、VEGFR2、VEGFR3,PDGFRa、PDGFRB等多種酪氨酸激酶，阻斷腫瘤生長(zhǎng)所需的血液和營(yíng)養(yǎng)物質(zhì)供給，具有抗腫瘤和抗血管生成作用[2-3]o既能直接攻擊腫瘤、又無常規(guī)化
8、療的毒副作用，其臨床優(yōu)勢(shì)
